Placebo News and Research

RSS

SGLT2 inhibitors can slow CKD progression

850 million people worldwide are affected by chronic kidney disease (CKD) - a worrying figure, and one that continues to rise.

31 Aug 2020

Gout medication reduces major cardiovascular events in heart patients

Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.

31 Aug 2020

Antihypertensive drugs are not linked to cancer, shows study

There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to the most extensive study conducted on the topic. The late breaking research is presented today at ESC Congress 2020.

31 Aug 2020

$Empagliflozin reduces risk of death in patients with heart failure and reduced ejection fraction$

Empagliflozin reduces risk of death in patients with heart failure and reduced ejection fraction

Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.

31 Aug 2020

Study: Mavacamten improves heart function in patients with hypertrophic cardiomyopathy

Mavacamten improves heart function and symptoms in patients with obstructive hypertrophic cardiomyopathy, according to results of the EXPLORER-HCM trial presented in a Hot Line session today at ESC Congress 2020.

31 Aug 2020

DAPA-CKD trial shows dapagliflozin reduces risk of chronic kidney disease

Dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalization and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes.

31 Aug 2020

Trimetazidine does not improve outcomes in patients with chronic or acute coronary syndromes

Trimetazidine administered after successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes, according to results of the ATPCI trial presented in a Hot Line session today at ESC Congress 2020.

31 Aug 2020

A coffee and quick catnap can improve alertness during nightshift

A simple coffee and a quick catnap could be the cure for staying alert on the nightshift as new research from the University of South Australia shows that this unlikely combination can improve attention and reduce sleep inertia.

28 Aug 2020

5 things to know about convalescent blood plasma

President Donald Trump told the American people this week that convalescent plasma is a potential new treatment for COVID-19.

27 Aug 2020

Gout drug may improve heart function in individuals with congenital heart disease

A drug used to treat gout, probenecid, may improve heart function in individuals with a particular heart defect, according to results from a small pilot study run by a University of Cincinnati researcher.

27 Aug 2020

Researchers identify how promising therapy may work to improve adverse effects of NAFLD

A team led by researchers at Massachusetts General Hospital (MGH) has taken an important step forward in the goal of developing a potential treatment for non-alcoholic fatty liver disease (NAFLD), the most common form of chronic liver disease.

26 Aug 2020

Consuming personal fecal microbiome when dieting may limit weight regain, study shows

People who consume frozen microbiome capsules derived from their own feces when dieting may limit their weight regain, according to a new study published in Gastroenterology, conducted by a team of researchers led by researchers at Ben-Gurion University of the Negev.

26 Aug 2020

LA hospital seeks vaccine trial participants among its own high-risk patients

The patients at Dr. Eric Daar's hospital are at high risk for serious illness from COVID-19, and he's determined to make sure they're part of the effort to fight the disease.

26 Aug 2020

Vitamin D supplements do not prevent severe asthma attacks in children

Contrary to earlier results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.

25 Aug 2020

UH to participate as study site for Pfizer and BioNTech's COVID-19 vaccine

University Hospitals announced today plans to participate as a study site for the Phase 2/3 global study sponsored by Pfizer Inc. and BioNTech SE of an investigational vaccine, BNT162b2, against SARS-CoV-2.

24 Aug 2020

Research suggests seaweed extract and xylitol may help protect against COVID-19

Researchers in the United States have demonstrated the antiviral effect of three candidate nasal spray formulations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

24 Aug 2020

Pfizer/BioNTech COVID-19 vaccine candidate BNT162b2 profiled for large scale clinical trials

Although two RNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates elicited similar, dose-dependent neutralizing antibody titers in both younger and older adults, a recent study by researchers from the U.S. and Germany has shown that BNT162b2 is associated with less systemic reactogenicity in elderly individuals – supporting its selection for further phase 2/3 clinical trials. The study is currently available on medRxiv* preprint server.

23 Aug 2020

VUMC receives $34 million grant for nationwide convalescent plasma study

Vanderbilt University Medical Center has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of "convalescent plasma" as a treatment for COVID-19.

21 Aug 2020

New SARS-CoV-2 vaccine effective in macaques

Researchers from the biotechnology company Novavax in Gaithersburg, Maryland, have developed a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that successfully induces immunogenicity and protection against the virus in macaques.

20 Aug 2020

Drug used in rheumatoid arthritis and cancer treatment improves survival in critically ill COVID-19 patients

Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,000 hospitalized COVID-19 patients to show that a drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU).

20 Aug 2020

Placebo News and Research

SGLT2 inhibitors can slow CKD progression

Gout medication reduces major cardiovascular events in heart patients

Antihypertensive drugs are not linked to cancer, shows study

Empagliflozin reduces risk of death in patients with heart failure and reduced ejection fraction

Study: Mavacamten improves heart function in patients with hypertrophic cardiomyopathy

DAPA-CKD trial shows dapagliflozin reduces risk of chronic kidney disease

Trimetazidine does not improve outcomes in patients with chronic or acute coronary syndromes

A coffee and quick catnap can improve alertness during nightshift

5 things to know about convalescent blood plasma

Gout drug may improve heart function in individuals with congenital heart disease

Researchers identify how promising therapy may work to improve adverse effects of NAFLD

Consuming personal fecal microbiome when dieting may limit weight regain, study shows

LA hospital seeks vaccine trial participants among its own high-risk patients

Vitamin D supplements do not prevent severe asthma attacks in children

UH to participate as study site for Pfizer and BioNTech's COVID-19 vaccine

Research suggests seaweed extract and xylitol may help protect against COVID-19

Pfizer/BioNTech COVID-19 vaccine candidate BNT162b2 profiled for large scale clinical trials

VUMC receives $34 million grant for nationwide convalescent plasma study

New SARS-CoV-2 vaccine effective in macaques

Drug used in rheumatoid arthritis and cancer treatment improves survival in critically ill COVID-19 patients

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News